PD-161570

Research use only, not for human use.

PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively.

PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively.

PD-161570 (Compound 6c; 0.1-1 μM; 1-8 days; VSMCs) treatment inhibits PDGF-stimulated vascular smooth muscle cell proliferation in a dose dependent fashion with an IC50 of 0.3 μM on day 8.PD-161570 suppresses constitutive phosphorylation of the FGF-1 receptor in both human ovarian carcinoma cells (A121(p)) and Sf9 insect cells overexpressing the human FGF-1 receptor and blocked the growth of A121(p) cells in culture.PD-161570 can potently inhibit basic fibroblast growth factor (bFGF)-mediated angiogenesis. Cell Proliferation Assay Cell Line:Vascular smooth muscles cells (VSMCs) Concentration:0.1 μM, 0.3 μM, 1 μM Incubation Time:1 day, 3 days, 6 days, 8 days Result:Inhibited VSMC proliferation in a dose dependent fashion with an IC50 of 0.3 μM at day 8.

——

PD 161570 | PD-161570

Angiogenesis

EGFR

——

——

——

192705-80-9

532.51

C26H35Cl2N7O

>98% (HPLC)

In Vitro:?DMSO : 33.33 mg/mL (62.59 mM)

CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl

——

(-20℃)

With Ice Pack

≥ 2 years